Dimerix LimitedASX: DXB

New Data Supports Biological Rationale for DMX-200 in FSGS

· Issued by Dimerix Limited via ASX

Filed with ASX ·

For Immediate Release NEW HUMAN DATA STRENGTHENS BIOLOGICAL RATIONALE FOR DMX-200 IN FSGS Highlights • New data presented at Kidney Week 2026 provides additional biological evidence supporting the 1 2 inflammatory mechanism of action of DMX-200 which targets CCR2 in FSGS • Independent...

View Attachment

6ix is reading this filing.

Dimerix Limited on 6ix

Earlier from Dimerix

All Dimerix news releases